Warren Christopher, Galli Jennifer D, Bystol Karin, O'Donnell Gregory, Swartz Andrew R, Dewar Emily A, Fulton Corey May, Shen Pamela, Gonzalez-Fernandez Estibaliz, DeWitt Lizzy Aurora, Jeong Uijin, Pan Oscar Chi-Chien, Miller Sean, Fridman Arthur, David Courtney, Chen Zhifeng, Wei Jiajie
Infectious Diseases and Vaccines Discovery, Merck & Co., Inc., West Point, PA, USA.
Quantitative Biosciences, Merck & Co., Inc., West Point, PA, USA.
NPJ Vaccines. 2025 Aug 19;10(1):196. doi: 10.1038/s41541-025-01254-2.
Noroviruses are non-enveloped, single-stranded positive-sense RNA viruses and the leading cause of gastroenteritis worldwide. The major capsid protein, VP1, can self-assemble into non-infectious virus-like particles (VLPs), representing an attractive vaccine platform. It was demonstrated that engineered disulfide bonds within VP1 could significantly stabilize VLPs of the archetypal GI.1 strain. Here, we apply a similar strategy to VLPs of multiple circulating GII genotypes. We find that engineered disulfide mutations can significantly stabilize VLPs of the GII.3 strain, but not the closely related GII.6 strain. Disulfide-stabilized GII.3 VLPs (GII.3-DS1) exhibit increased yields, greater homogeneity, and higher thermal stability compared to wild-type GII.3 VLPs. GII.3-DS1 VLPs are a superior reagent in immunological assays compared to the wild-type counterpart. Importantly, mRNA encoding GII.3-DS1 elicits superior humoral immune responses compared to wild-type GII.3 mRNA in mice. These results demonstrate the utility of rational VLP stabilization for advancing vaccine development efforts.
诺如病毒是无包膜的单链正义RNA病毒,是全球范围内肠胃炎的主要病因。主要衣壳蛋白VP1可自组装成无感染性的病毒样颗粒(VLP),是一个有吸引力的疫苗平台。研究表明,VP1内的工程二硫键可显著稳定原型GI.1毒株的VLP。在此,我们将类似策略应用于多种流行的GII基因型的VLP。我们发现,工程二硫键突变可显著稳定GII.3毒株的VLP,但对密切相关的GII.6毒株无效。与野生型GII.3 VLP相比,二硫键稳定的GII.3 VLP(GII.3-DS1)产量增加、均一性更高且热稳定性更高。与野生型对应物相比,GII.3-DS1 VLP在免疫测定中是一种更优的试剂。重要的是,与野生型GII.3 mRNA相比,编码GII.3-DS1的mRNA在小鼠中引发更强的体液免疫反应。这些结果证明了合理的VLP稳定化对推进疫苗开发工作的实用性。